

## Press Release

# Bilthoven Biologicals Appoints New CEO: Jurgen Kwik

**BILTHOVEN, NETHERLANDS, MARCH 2024 - Bilthoven Biologicals (BBio) is pleased to announce the appointment of Mr. Jurgen Kwik as its new Chief Executive Officer (CEO).**

Mr. Kwik brings extensive experience in the Life Sciences sector. His tenure includes leadership positions such as the leader of the Global COVID-19 Vaccine Program Office and, more recently, Global Head Portfolio Strategy & Site Operations; Infectious Diseases & Vaccines R&D at Janssen.



### About Jurgen Kwik

Mr. Kwik has held various leadership roles across different sectors and geographies. His diverse international experience, collaborating with teams in Europe, Asia, and the United States, has shaped his leadership style. He fosters collaboration, inclusivity, and trust and has a strong sense of context and perspective. As a board member, Mr. Kwik has been actively involved in shaping vaccine strategies.

### Vision for Bilthoven Biologicals

Mr. Kwik's vision aligns with BBio's growth-oriented, challenging and results-driven work environment. He aims to continue the company's legacy of producing high-quality and affordable vaccines while driving innovation and transformation.

### Acknowledgment

Directors at BBio and the Serum Institute of India express their confidence in Mr. Kwik's ability to lead the organization effectively. Mr. Adar Poonawalla, Chairman of Serum Institute of India, stated, "We are delighted to welcome Jurgen Kwik as new CEO for the subsidiary BBio. His extensive experience and leadership will be instrumental in advancing our mission to improve global health."

Mr. Kwik will assume his role as CEO on April 2nd, 2024.

### About Bilthoven Biologicals B.V.

Since 2012, BBio, a subsidiary of the Serum Institute of India Pvt., Ltd., has been producing vaccines on the Utrechts Science Park Bilthoven. The company specializes in polio vaccines and is also the exclusive supplier of BCG for post-treatment of bladder cancer. Recently, BBio was awarded a pandemic preparedness contract by the European Commission. The framework agreement focuses on pandemic preparedness, including the production and supply of viral vector vaccines in emergency situations in Europe.

---

Note for editors: if you want more information on this press release, please contact the communications manager at Bilthoven Biologicals: Arlette Kessing via [arlette.kessing@bbio.nl](mailto:arlette.kessing@bbio.nl)